Balanced Translocation and IVF: When Is PGT-SR Worth Discussing?

The rearrangement described on a laboratory report matters more than the word “balanced.” A clinician and genetic counsellor should review the chromosomes involved, family history and any previous pregnancy or miscarriage results. Some unusual findings require additional characterisation before treatment planning.

PGT-A evaluates numerical chromosome abnormalities in selected IVF contexts; PGT-SR is designed for known structural rearrangement risks. The technologies and reporting limits can differ between laboratories. A single sales phrase such as “complete embryo screening” hides distinctions that affect consent and interpretation.

Embryo appearance under the microscope cannot reveal balanced or unbalanced chromosomal arrangements. Conversely, genetic reports may have uncertainty that deserves counselling. Biopsy, freezing and testing add stages and cost to an IVF cycle; they should follow a clear, legally appropriate indication.

A result from preimplantation testing is not a complete replacement for all prenatal screening or diagnostic options. The counselling team should explain what residual risks remain and when a prenatal genetics service may be consulted after pregnancy. Patients deserve written information rather than a promise of certainty.

The Assisted Reproductive Technology (Regulation) Act sets rules relevant to use of preimplantation genetic testing. Clinics and laboratories must assess the legal indication, consent and applicable protocols for the individual case. Nonmedical sex selection or general enhancement claims must not be presented as valid reasons for testing.

Some cycles may yield no embryos suitable for transfer after the indicated testing; outcomes depend on many factors including age and embryo development. Discuss whether to proceed with IVF, consider other reproductive pathways or seek another specialist opinion before beginning expensive treatment.